Hong Kong Stock Volatility | Innovative Drug Concept Gains Strength, Biopharmaceuticals First to Enter "Emerging Pillar Industries" BD and Performance Expected to Drive Double Growth

LootboxPhobia · 2026-03-06T03:23:48+00:00

The innovative drug concept performed strongly in the early trading session, with shares of multiple pharmaceutical companies rising. Influenced by the government's designation of biomedicine as an "emerging pillar industry," the industry outlook is optimistic. Analysts recommend focusing on companies with performance exceeding expectations, which is expected to drive the sector higher.

LootboxPhobia

2026-03-06 03:23:48

Abstract generation in progress

SmartInsight Financial APP reports that the innovative drug sector strengthened early in the trading session. As of the latest update, Hutchison Medicine (00013) rose 9.02% to HKD 22.96; Sino Biopharmaceutical (01530) increased 8.41% to HKD 21.4; Hengrui Medicine (01276) gained 5.45% to HKD 65.75; Innovent Biologics (01801) went up 5.42% to HKD 82.7; Consonant Bio-B (02162) increased 5% to HKD 50.4.

In terms of news, the government work report from this year’s National Two Sessions explicitly listed biopharmaceuticals as a “new pillar industry” at the national level, alongside industries like integrated circuits, aerospace, and low-altitude economy. This is the first time the development of the biopharmaceutical industry has been proposed as a pillar industry in the government work report, signaling an important policy move to accelerate industry upgrading.

Southwest Securities believes that multiple companies announcing cooperation and licensing agreements verify their R&D strength. The total BD (business development) contracts in the first two months of 2026 have exceeded $50 billion, nearly 40% of the total for 2025, with initial payments surpassing $3 billion, also over 40% of 2025’s total. The fundamentals of the innovative drug sector continue to improve. CMB International points out that this week, companies are gradually releasing earnings forecasts. It is recommended to keep an eye on companies with better-than-expected financial performance and clear profit paths, as their earnings realization could catalyze sector momentum.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.